Market Overview

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Related IDXX
Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROA
IDEXX Laboratories Elects Daniel Junius to Board of Directors
Related NEOG
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Earnings Scheduled For March 25, 2014

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year.

Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter.

Neogen (NASDAQ: NEOG) is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%.

Meridian Bioscience (NASDAQ: VIVO) is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%.

Abaxis (NASDAQ: ABAX) may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.

Posted-In: Diagnostic Substances Industry Highest Revenue Estimates NASDAQ StocksTrading Ideas

 

Most Popular

Related Articles (ABAX + IDXX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free